Agarikon (Fomitopsis officinalis)
Agarikon (Fomitopsis officinalis)
Agarikon (Fomitopsis officinalis) is a large, shelf-like bracket fungus native to old-growth conifer forests of the Northern Hemisphere, producing chalky column-shaped fruiting bodies. It is one of the longest-lived fungal fruiting bodies known to science and has been used medicinally for over 2,000 years — documented from ancient Greece through to modern clinical research. Today it is one of the rarest fungi in the world due to the loss of old-growth forest habitat it depends on.
Fomitopsis officinalis (Vill.) Bondartsev & Singer (1941) · syn. Laricifomes officinalis (Vill.) Kotl. & Pouzar · Family Fomitopsidaceae · Order Polyporales
Agarikon (Fomitopsis officinalis) is a perennial old-growth polypore conk whose medicinal use is documented without interruption for two millennia — from Dioscorides prescribing it for tuberculosis in the first century CE to a randomized controlled trial published in BMC Immunology in March 2026. It is one of the most pharmacologically complex fungi studied, containing over 60 identified secondary metabolites distributed across distinct tissue types: chlorinated coumarins concentrated in the mycelium, lanostane triterpenoids in the fruiting body, and structurally unusual polysaccharides in both. The species cannot be commercially farmed in the conventional sense — its fruiting bodies grow at geological speed, adding one pore layer per year — but its mycelium is fully cultivable in liquid culture and produces the coumarin compound class specifically linked to anti-tuberculosis activity.
Interested in this species? Out-Grow carries a liquid culture.
Agarikon (Fomitopsis officinalis) Liquid CultureWhat Is Agarikon (Fomitopsis officinalis)?
Agarikon (Fomitopsis officinalis) is a sessile, hoof-shaped to columnar polypore — a bracket fungus that grows directly from the trunks of old conifer trees without a stalk. Unlike the soft, ephemeral fruiting bodies of most edible mushrooms, agarikon builds a hard, perennial conk that adds a new pore layer every growing season, exactly as a tree adds annual rings. In this way, a single agarikon fruiting body is not a seasonal event but a decades-long accumulation of biological growth, with documented specimens reaching 60–75 years of age and weights approaching 10 kg. One specimen in the Fungi Perfecti collection was described reaching 75 cm in length.
The name agarikon derives directly from the ancient Greek and Latin "agaricum," as used by Dioscorides Pedanios in his De Materia Medica (c. 60 CE) — the encyclopedic pharmacological text that served as the foundation of European medicine for over a thousand years. Dioscorides prescribed agaricum against consumption (tuberculosis), pneumonia, and digestive disorders. That ancient anti-TB application, recorded without any knowledge of Mycobacterium tuberculosis, was confirmed two millennia later when Hwang et al. (2013) isolated two chlorinated coumarins from agarikon mycelial culture with documented inhibitory activity against M. tuberculosis, including drug-resistant strains. The alignment between pre-scientific empirical medicine and modern pharmacology in this species is explicit enough that the researchers themselves highlighted it.
The mycelium and fruiting body of agarikon are chemically different organisms. Chlorinated coumarins — the compound class with the most documented anti-TB activity — are concentrated in mycelium and mycelial culture extracts, and are absent or low in the fruiting body. The lanostane triterpenoids (anti-inflammatory, trypanocidal, potentially neuroprotective) are concentrated in the fruiting body. This means liquid culture mycelium and dried fruiting body powder are genuinely different products with different bioactive profiles — a distinction almost entirely absent from commercial supplement marketing.
In the Pacific Northwest, agarikon (Fomitopsis officinalis) occupies a cultural significance as deep as its ecological one. Nineteenth-century shaman grave guardians carved by Pacific Northwest Indigenous peoples — long assumed to be wooden — were identified in 1992 by microscopy and chemical analysis as carved agarikon fruiting bodies. The Indigenous name "Bread of Ghosts" reflects the fungus's spectral appearance: pale, chalk-white, hanging like a calcified form from ancient forest giants. Paul Stamets, who has collected over 60 strains from Pacific Northwest old-growth forests and documented significant strain-to-strain variation in antiviral activity, brought the species to wider public attention through his writing and through a collaboration with NIAID and USAMRIID that screened agarikon extracts against poxvirus, H5N1 influenza, and other high-priority pathogens.
Today, agarikon (Fomitopsis officinalis) is commercially endangered across most of its European range — extinct in Ukraine, critically endangered in much of the Alps — and is functionally extinct across large areas of its former North American range following old-growth logging. Its conservation status, its extreme slowness in culture, and its rich and incompletely understood chemistry make it simultaneously one of the most scientifically important and most practically challenging fungal species for any cultivator or researcher to work with.
How Is Agarikon (Fomitopsis officinalis) Classified?
The taxonomy of agarikon (Fomitopsis officinalis) involves two names in active parallel use — an unusual situation that reflects a genuine unresolved nomenclatural tension between the research literature and molecular taxonomy.
| Rank | Name |
|---|---|
| Kingdom | Fungi |
| Phylum | Basidiomycota |
| Subphylum | Agaricomycotina |
| Class | Agaricomycetes |
| Order | Polyporales |
| Family | Fomitopsidaceae |
| Genus | Laricifomes (accepted) / Fomitopsis (widely used in research) |
| Species epithet | officinalis — Latin for "of the apothecary / medicinal shop" |
The basionym (original name from which all later names derive) is Boletus officinalis Vill. (1789). From there, the synonymy chain runs through four further combinations as knowledge of polypore systematics evolved: Polyporus officinalis (Vill.) Fr. (1821), Fomes officinalis (Vill.) Bres. (1900), Fomitopsis officinalis (Vill.) Bondartsev & Singer (1941), and finally Laricifomes officinalis (Vill.) Kotl. & Pouzar (1972).
The current situation: Fomitopsis officinalis is the name used in the overwhelming majority of published pharmacological research, mycelial culture work, and supplement industry documentation. Laricifomes officinalis is the molecularly supported currently accepted name — Han et al. (2016, Fungal Diversity) demonstrated through multi-gene phylogenetic analysis that F. officinalis forms a clade separate from the core Fomitopsis cluster. Index Fungorum ID for Laricifomes officinalis: 297501. Major databases remain inconsistent: GBIF lists Fomitopsis officinalis as its primary record, while the 2025 Frontiers review on the Fomitopsis genus uses Fomitopsis officinalis throughout.
For this guide, Fomitopsis officinalis is used as the primary scientific name — as the research literature standard — with Laricifomes officinalis acknowledged as the molecularly supported accepted name. This reflects both real-world search behavior and the state of the scientific record. The species epithet officinalis — shared by both names — translates as "of the apothecary" or "used in medicine," a designation earned over 2,000 years of continuous pharmacological documentation.
How Do You Identify Agarikon (Fomitopsis officinalis)?
Agarikon (Fomitopsis officinalis) is one of the most morphologically distinctive polypores in Northern Hemisphere old-growth forests. Its identification relies more on gestalt — the combination of habitat, form, texture, and taste — than on microscopy, as its macroscopic features are largely unique among temperate bracket fungi.
The single most useful field identification character is texture. Pressing a thumbnail firmly into the surface of an agarikon fruiting body produces a visible impression and leaves powdery residue — the flesh gives and crumbles rather than resisting. This chalky, friable quality is profoundly different from the hard, corky flesh of Fomitopsis pinicola (red-belted polypore) or the dense woody flesh of Ganoderma species. Combined with the extreme bitterness and the columnar shape on old conifer in a Pacific Northwest or Alpine old-growth forest, the identification is essentially unambiguous.
Lookalike Species
Fomitopsis pinicola (Red-Belted Polypore)
The most common confusion species. Distinguished by: hard, corky, tough flesh (does not crumble); distinctive red-orange to reddish-brown band near margin in fresh specimens; younger specimens have a resinous, shiny cap surface that exudes resin droplets when fresh. Flesh is not chalky. Very common on conifers; agarikon is rare.
Ganoderma species (Reishi relatives)
Distinguished by: woody, extremely hard flesh that does not crumble; many species have a distinctive lacquered, shiny upper surface; pore surface bruises brown when scratched; spores are double-walled and truncate. No chalky texture. Typically on hardwoods in North America; agarikon is on conifers.
Phellinus / Porodaedalea spp.
Hard, woody, dark brown to black conks on conifers. Distinguished immediately by flesh color (rust-brown throughout, not white/cream), lack of crumbly chalk texture, and dark zones in cross-section. No flavor resembling agarikon's intense bitterness.
Old Fomes fomentarius (Tinder Fungus)
Hoof-shaped perennial conk on hardwoods (birch, beech). Distinguished by: grows on hardwoods, not conifers; thick, leathery to corky flesh with distinctly zoned cross-section of hard crust / spongy tube layer / dense context — not chalky throughout. Pores are grey-brown when mature.
Where Does Agarikon (Fomitopsis officinalis) Grow?
Agarikon (Fomitopsis officinalis) is a brown-rot fungus — it preferentially degrades cellulose while leaving lignin largely intact, producing the characteristic brown, cubically cracked decay visible inside affected trees. Ecologically it functions as a slow-growing necrotrophic parasite (an organism that kills the host tissue it colonizes): it enters living trees through wounds — broken branches, lightning strikes, mechanical damage to bark — colonizes the heartwood, and causes progressive brown heart rot. After the host tree dies, the conk continues growing saprotrophically (feeding on dead organic matter), persisting and expanding on the standing dead tree for decades.
This trophic mode is critical to understand for cultivation purposes. Agarikon is not mycorrhizal — it does not require a living tree root as a symbiotic partner, which is the fundamental barrier to cultivating species like truffles or matsutake. The barrier to commercial agarikon cultivation is speed, not biological dependency. Its mycelium grows at only 0.4–1.9 mm per day on agar, and fruiting bodies require years of perennial growth before reaching meaningful size. Dead wood substrate is biologically sufficient; the timescale is the obstacle.
| Region | Populations | Status |
|---|---|---|
| Pacific Northwest, North America | Washington, Oregon, British Columbia; old-growth conifer forests on Douglas fir, fir, hemlock, spruce, pine | Most robust global population; functionally extinct across large areas following old-growth logging |
| Alps, Western/Central Europe | Italy, Switzerland, Austria, France; primarily on larch (Larix decidua) | Fragmented; endangered in most countries; protected in national parks and reserves |
| Eastern Europe | Poland, Ukraine (historically) | Listed as extinct in Ukraine's Red Data Book; present but rare in Poland |
| Siberia / Russia | Ural-Siberian region; most common in Asian Russia per 2003 survey | Most abundant remaining Eurasian populations |
| Asia | Japan, Korea, northern China | Small populations; primarily on larch |
| North Africa | Morocco | Small populations documented |
Host preference differs between continents. In Eurasia, agarikon grows almost exclusively on larch (Larix spp.), particularly European larch (Larix decidua) in the Alps. In North America, the host range is considerably broader — Douglas fir (Pseudotsuga menziesii), true firs (Abies), spruces (Picea), pines (Pinus), hemlocks (Tsuga), and larches all documented as hosts.
Conservation note: Agarikon (Fomitopsis officinalis) is endangered to critically endangered across most of its European range and has been listed among the 33 threatened European fungi by the European Council for the Conservation of Fungi (ECCF). Primary threats are old-growth forest logging (the species requires large, old trees — it is entirely absent from young managed forests), historical over-harvesting for medicinal use, and climate-related shifts in the distribution of host larch forests. The species is listed as extinct in Ukraine's national Red Data Book. Verify current IUCN Global Red List status at iucnredlist.org before publication.
Can You Cultivate Agarikon (Fomitopsis officinalis)?
Agarikon (Fomitopsis officinalis) cannot be commercially cultivated for fruiting bodies on any practical timescale. This is not due to mycorrhizal dependency — it is a wood-rot saprotroph with no need for a living plant partner. The constraint is biological: its mycelium grows at 0.4–1.9 mm per day on agar, and fruiting bodies develop over years, adding one pore layer per growing season. At the lower growth rate, the mycelium advances slower than the hour hand of a watch. No published protocol produces commercial fruiting body flushes in any normal cultivation timeframe.
What is both achievable and scientifically documented is mycelial biomass cultivation in liquid culture — producing the compound class most relevant to anti-TB research, polysaccharides with immunomodulatory activity, and a substrate for strain maintenance and experimental work. Liquid culture of agarikon (Fomitopsis officinalis) is the correct production pathway for mycelium-specific bioactive compounds.
Agar Culture Parameters
Sterile technique is non-negotiable. The Hwang et al. 2013 Fungi Perfecti protocol used a Class 100 clean room for all cultivation stages of this species. At 0.4–1.9 mm/day, any contaminating organism that grows faster will outcompete agarikon completely. Trichoderma spp. (green mold), bacterial contamination, and fast-spreading ascomycetes are the primary risks. This is the most contamination-sensitive species most hobbyist cultivators will encounter.
Liquid Culture Parameters and Yields
The most detailed published liquid culture protocol for agarikon (Fomitopsis officinalis) is from Mykchaylova et al. (2024, Biotechnologia Acta DOI: 10.15407/biotech17.01.043), using an optimized GPY medium. The Hwang et al. (2013, Fungi Perfecti) protocol provides complementary data on mycelial fragmentation and substrate inoculation.
GPY Medium Composition
Glucose 30.0 g/L · Peptone 3.5 g/L · Yeast extract 2.0 g/L · KH₂PO₄ 1.0 g/L · K₂HPO₄ 1.0 g/L · MgSO₄·7H₂O 0.25 g/L · pH 5.5. Prepare in Erlenmeyer flasks; autoclave to sterilize.
Inoculation & Conditions
Inoculate at 10% by volume. Shake at 120 rpm; temperature 26 ± 1°C; dark; 12-day cultivation period. 100 mL medium per 500 mL flask produces reliable results. Dark incubation is the control baseline.
Light Stimulation (Optional)
Brief blue LED (470 nm) or blue laser (488 nm) irradiation of the inoculum preparation increases mycelial biomass ~15–20% vs. dark controls (p < 0.05), reaching 14.7 g/L dry weight at 12 days. Red LED (650 nm) stimulates exopolysaccharide synthesis specifically.
Documented Yields (12 days)
Dark control: ~11–13 g/L dry mycelium. Blue light optimized: 14.7 g/L dry mycelium. Exopolysaccharide production co-occurs with biomass. These are commercially realistic yields for supplement-grade biomass.
Substrate Inoculation (Hwang 2013)
Grow mycelium on malt extract yeast agar for 3 weeks (21–24°C), fragment in liquid using blender, use 50–100 mL myceliated broth to inoculate ~3 kg moistened sterile rice. Incubate 60–120 days in clean room conditions.
Experimental Fruiting Body Results
Mykchaylova et al. (2017) produced the most detailed published fruiting body attempt: on sunflower husk substrate, complete mycelial colonization occurred by day 30 and fruit bodies developed. On larch chip substrate, approximately 50% colonization by days 30–40 also produced fruit bodies. On larch sawdust, only 27% colonization after 60 days with no primordia. This confirms fruiting is biologically achievable — but the timeline for meaningful body size remains impractical commercially. The sunflower husk result is notable: larch wood is not biologically necessary, suggesting more substrate flexibility than wild host specificity implies.
Conservation Inoculation of Living Larch Trees
Two published studies demonstrate that liquid culture inoculum can be used to establish agarikon in living larch trees — relevant both for conservation biology and for anyone interested in long-term fruiting body production in managed larch plantations. Gregori et al. (Slovenia) achieved 83.3% mycelial re-isolation success from two inoculated living larches over three years under optimal conditions. Piętka & Grzywacz (Poland) confirmed live mycelium by PCR-RFLP at three years post-inoculation in 30 larches and 20 stem sections. These protocols demonstrate that liquid culture inoculum can establish viable mycelial colonies in a living host tree — the starting point for a decades-long fruiting body development trajectory.
Agarikon Liquid Culture — What It Contains and How to Use It
Out-Grow's Agarikon (Fomitopsis officinalis) liquid culture contains actively growing mycelium of a vigorous agarikon strain suspended in sterile nutrient solution. The peer-reviewed literature documents optimal liquid culture conditions at 26°C, pH 5.5, 120 rpm agitation in GPY medium, producing 11–15 g/L dry mycelial biomass in 12 days — commercially viable yields for supplement-grade production. Critically, mycelial culture is the correct source for agarikon's chlorinated coumarin compound class, which is concentrated in mycelium and culture extracts and absent or low in fruiting body tissue. This means liquid culture is not a consolation prize for a species that can't be fruited — it is the correct production pathway for the most pharmacologically documented compound class in the organism. Additional applications: agar expansion for strain maintenance or research plate work; experimental substrate colonization trials; and living larch tree inoculation for conservation or long-term cultivation projects. Do not market or purchase this liquid culture with the expectation of producing conventional fruiting body flushes on a normal cultivation timeline.
What Bioactive Compounds Does Agarikon (Fomitopsis officinalis) Contain?
Agarikon (Fomitopsis officinalis) contains 60–115 identified secondary metabolites depending on the source reviewed — an unusually rich and chemically diverse profile for a single fungal species. The defining feature of its chemistry is tissue-specific partitioning: different compound classes are produced in different parts of the organism, and this partitioning has direct practical implications for what substrate to use and what biological activity to expect.
Chlorinated Coumarins (from MYCELIUM)
In Vitro OnlyTwo naturally occurring chlorinated coumarins isolated from mycelial culture EtOH extract (Hwang et al. 2013). Compound 2 (ethyl 6-chloro-2-oxo-4-phenyl-2H-chromene-3-carboxylate): MIC₉₀ 44.7 µg/mL vs M. tuberculosis H37Rv (replicating) and 37.1 µg/mL (non-replicating); active against drug-resistant strains (rRMP, rINH, rSM) at 44.7–49.5 µg/mL. Selectivity index 0.82 — poor as a direct drug candidate, but an important structural pharmacophore. Absent or low in fruiting body; mycelium is the correct source.
Lanostane Triterpenoids (from FRUITING BODY)
In Vitro + AnimalThe largest compound class with 20+ characterized members including fomefficinic acids A–G, officimalonic acids A–H, fomitopsins A–H, eburicoic acid, and sulfurenic acid. Selected activities: fomitopsins F, G, H show trypanocidal activity against Trypanosoma congolense (IC₅₀ 7.0–27.1 µM); officimalonic acids D, E, G, H and fomitopsin A show anti-inflammatory activity in vitro; dehydrosulfurenic acid is patented for neuroprotective use in ischemic stroke models. Concentrated in fruiting body.
Polysaccharides FOBP50-1 and FOBP90-1
In Vitro + Zebrafish ModelTwo structurally characterized polysaccharides from the fruiting body. FOBP50-1 (MW 2.21 × 10⁴ g/mol): galactose-dominant composition; antitumor activity in zebrafish via TLR-4, PD-1, and VEGF interactions. FOBP90-1 (MW 2.87 × 10⁴ g/mol): anticancer activity via TLR-2, TLR-4, PD-L1, VEGFR-2 pathways in zebrafish. Branched β-glucans also characterized; cytotoxic activity documented. No human pharmacokinetic or clinical data for these specific compounds.
Phenolic Compounds
In VitroSpatial analysis of fruiting body parts (Angeles Flores et al. 2023): apical portion shows highest total phenolic content (TPC 116.12 mg GAE/100g), DPPH antioxidant capacity (104.06 mg TE/100g), and FRAP (198.00 mg TE/100g). Quercetin identified as the major phenolic compound by HPLC. Mycelial phenolic content in liquid culture: 48.11–84.72 mg GAE/g dry mass depending on light treatment; blue-laser irradiation produces highest values.
Agaric Acid (Agaricinic Acid)
Pharmacological — Dose DependentA trihydroxy fatty acid responsible for the characteristic intense bitterness. Historically used as an anticholinergic and antiperspirant agent; biological properties have been compared to atropine. Causes anticholinergic effects (dryness, reduced secretions), purgative effects, and emetic effects at high doses. At standard supplement doses from dried mycelium or extract, pharmacological effects are not expected. No case reports of toxicity at supplement doses in the literature.
Antiviral Extracts (Crude)
In Vitro / Cell CultureCrude mycelial extracts screened by Stamets et al. in collaboration with NIAID and USAMRIID showed activity against poxvirus (described as "extraordinarily active" by Dr. John Secrist), H5N1 influenza (A/chicken/Kurgan/05/2005) and H3N2, and Orthopoxvirus. HSV-1 inhibition attributed to fomitopsin D. The specific compound(s) responsible for poxvirus activity have not been isolated and characterized — a major research gap. All results are from crude or partially purified mycelial extracts.
Mycelium vs. fruiting body — practical implication: The chlorinated coumarins with anti-TB activity are a mycelium-specific compound class. Fruiting body powder products will contain triterpenoids and polysaccharides but not the coumarin pharmacophore. Liquid culture mycelium products will contain coumarins, polysaccharides, and phenolics — but not the full triterpenoid profile of an aged fruiting body. These are genuinely different bioactive preparations from the same organism. Claims that conflate mycelium and fruiting body extract are scientifically inaccurate for this species.
Is Agarikon (Fomitopsis officinalis) Safe to Eat?
Agarikon (Fomitopsis officinalis) is not classified as toxic or poisonous in standard mycology toxicology references, and no poisoning case reports exist in the literature at supplement doses. However, "not toxic" is not the same as "food" — the intensely bitter taste from agaric acid makes the fruiting body wholly inedible as a culinary ingredient, and the species has never been consumed as a food mushroom in the way that oyster or shiitake mushrooms are eaten. Its historical and contemporary use is entirely as a medicinal preparation: dried and powdered, as a tea, or as an extract.
The most important safety data point is the FoTv randomized controlled trial (Saxe et al. 2026, BMC Immunology): over a 6-month study period in 90 adults, the FoTv preparation combining F. officinalis and Trametes versicolor mycelium showed no adverse events in either the treatment or placebo group. This is the strongest safety data currently available for this species in human subjects at supplement doses.
The agaric acid pharmacology warrants mention: at very high doses, agaric acid can cause anticholinergic effects (excessive dryness, reduced secretions), laxative effects, and at extreme doses, emetic effects. These reflect the historical use of large doses as a purgative and antiperspirant in medieval medicine. Standard commercial mycelium supplement doses present no documented risk. As with all immunomodulatory mushroom products, theoretical interactions with immunosuppressive medications (such as those used after organ transplantation) cannot be excluded on general pharmacological principles — consult a physician if taking immunosuppressants.
What Makes Agarikon (Fomitopsis officinalis) Remarkable?
Among medically and scientifically studied fungi, agarikon (Fomitopsis officinalis) occupies a position with few equivalents — a species documented by ancient physicians, ignored for centuries of modern medicine, then rediscovered by molecular pharmacologists who found the ancient empirical observations had been right all along.
One of the Longest-Lived Fruiting Bodies on Earth
A single agarikon conk can be continuously alive for 60–75 years, adding a new layer of pores each growing season like a tree adds annual rings. At 75 years, one fruiting body has been alive through multiple human generations. This extreme longevity raises fundamental questions about fungal senescence — whether fungi age in a biologically meaningful sense, how cellular repair operates over decade-long timescales in fungal tissue, and what the maximum possible lifespan of a fungal fruiting body actually is — questions that are almost entirely unstudied.
Two Thousand Years of Documented Pharmacological Use
Dioscorides prescribed "agaricum" against consumption — tuberculosis — in the first century CE. Modern laboratory work isolated two chlorinated coumarins from agarikon mycelium with documented inhibitory activity against Mycobacterium tuberculosis, including drug-resistant strains. This two-millennium gap between empirical observation and laboratory confirmation, in which the ancient conclusion proved directionally correct, is one of the more compelling examples in all of ethnopharmacology. The researchers who published the coumarin isolation study explicitly highlighted this alignment.
Shaman Grave Guardians
The discovery that 19th-century Pacific Northwest Indigenous shaman grave guardians — wooden post-like objects carved with faces, held in museum collections — were in fact carved agarikon fruiting bodies (Blanchette et al. 1992, Mycologia 84:119–124) is one of the stranger facts in mycological history. The carved conks had survived for over a century in museum conditions before microscopy and chemical analysis revealed their true identity. Their use reflects both the physical durability of aged agarikon conks — which can persist for decades after the host tree dies — and their deep cultural significance to Pacific Northwest Indigenous peoples, who called the fungus "Bread of Ghosts."
Compound Class Partitioned by Tissue Type
The tissue-specific partitioning of agarikon's chemistry — coumarins in mycelium, triterpenoids in fruiting body — is an unusual biological feature with direct pharmacological and commercial consequences. Most fungal secondary metabolites are present across tissue types in varying concentrations; in agarikon, entire compound classes are functionally absent from one tissue and present in another. The regulatory mechanism behind this partitioning — why the mycelium produces anti-TB coumarins but not triterpenoids, while the fruiting body does the reverse — is entirely unknown and represents one of the species' most interesting unresolved biological questions.
Antiviral Activity at Striking Scale
The 2018 field study by Stamets et al. (Scientific Reports) documented a 79-fold reduction in Deformed Wing Virus and a 45,000-fold reduction in Lake Sinai Virus in honeybee colonies fed a combined polypore mushroom extract syrup — results that, if they hold under replication, represent one of the most potent antiviral effects documented for any natural product. The mechanistic hypothesis is that β-glucans in the extract activate immune receptors (Dectin-1, TLR receptors) that are evolutionarily ancient and shared between insects and mammals — suggesting the antiviral mechanism may be conserved across animal phyla. The study used a combined extract and cannot be attributed to agarikon alone, but agarikon was a component, and separate NIAID/USAMRIID screening of agarikon extracts specifically against poxvirus has been described as showing "extraordinarily active" results.
Strain-Specific Variation in Antiviral Activity
Stamets' work comparing over 60 strains from Pacific Northwest collections found significant strain-to-strain differences in antiviral activity profiles. The Italian Alps study similarly found significant growth rate variation between strains from different Alpine populations. This means the biological activity of commercially available agarikon cultures is not standardized and may differ substantially between sources — a scientific puzzle (what genetic or chemical differences underlie it?) and a practical concern for anyone working with the species for pharmaceutical purposes.
Frequently Asked Questions About Agarikon (Fomitopsis officinalis)
What is agarikon and where does it grow?
Agarikon (Fomitopsis officinalis) is a perennial polypore conk that grows on old conifer trees in old-growth forests of the Northern Hemisphere — primarily the Pacific Northwest of North America, the European Alps, and Siberia. It produces large, chalk-textured, columnar fruiting bodies that grow directly from the trunk of living and dead trees, adding one pore layer per year and persisting for 60–75 years. It is now endangered to critically endangered across most of its European range due to old-growth forest logging and historical over-harvesting.
Is agarikon the same as the "quinine conk"?
The name "quinine conk" is a common name found in some North American foraging guides, but it is inaccurate — agarikon contains no quinine and has no anti-malarial properties. The name likely arose from confusion between the species' intense bitterness (caused by agaric acid, not quinine) and the bitter taste associated with quinine-containing plants. The correct common name is agarikon, derived directly from the ancient Greek and Latin term used by Dioscorides in the first century CE. Avoid using "quinine conk" in any medical or pharmacological context, as it implies a biological activity the species does not possess.
Can you cultivate agarikon mushrooms at home?
Fruiting body cultivation of agarikon (Fomitopsis officinalis) is not practically achievable on any normal timeframe — the mycelium grows at 0.4–1.9 mm per day and fruiting bodies develop over years, adding one pore layer per growing season. No published protocol produces commercial fruiting body flushes in a practical timeframe. What is achievable is mycelial biomass production in liquid culture, which yields 11–15 g/L dry biomass in 12 days under documented conditions. Mycelium-specific compounds — including the chlorinated coumarins linked to anti-TB activity — are present in mycelial culture and absent from fruiting body tissue, making liquid culture the correct production pathway for that compound class.
What are the health benefits of agarikon?
The most scientifically documented activities of agarikon (Fomitopsis officinalis) are: anti-tuberculosis activity of chlorinated coumarins isolated from mycelium (in vitro, including drug-resistant strains); anti-inflammatory and trypanocidal activity of lanostane triterpenoids from fruiting body (in vitro); antitumor activity of polysaccharides in zebrafish models; and preliminary human evidence from the FoTv RCT (2026), which found that a combined agarikon + turkey tail mycelium preparation taken during COVID-19 vaccination reduced vaccine side effects and extended antibody persistence in COVID-naive participants. All current evidence for specific health benefits beyond the RCT safety data is preclinical — in vitro or animal model only. No health claims should be made beyond what this evidence supports.
What is the difference between Fomitopsis officinalis and Laricifomes officinalis?
They are the same species — the same organism designated by two names reflecting different interpretations of its generic placement. Fomitopsis officinalis is the name used in the large majority of published pharmacological research and supplement documentation. Laricifomes officinalis is the molecularly supported currently accepted name, based on multi-gene phylogenetic analyses showing this species belongs in its own genus separate from the core Fomitopsis cluster. Major databases remain inconsistent in which name they use. Both names refer to the same organism; the choice between them reflects where a database or researcher draws the generic boundary, not a biological difference in the organism itself.
What is the agarikon liquid culture used for?
Out-Grow's Agarikon (Fomitopsis officinalis) liquid culture is used primarily for mycelial biomass production — yielding 11–15 g/L dry mycelium in 12 days under documented GPY medium conditions, a commercially viable yield for supplement or research applications. It is also used for agar expansion and strain maintenance, substrate colonization experiments (sunflower husk and larch chip substrates have produced fruiting bodies in published trials), and living larch tree inoculation for conservation projects. A critical distinction: mycelium is the specific source of agarikon's chlorinated coumarins, the compound class with documented anti-TB activity in vitro. Liquid culture is not a workaround for an uncultivable species — it is the scientifically correct production pathway for these specific compounds.
Also available as a culture plate from Out-Grow.
Agarikon (Fomitopsis officinalis) Culture Plate